From glycolytic signatures to patients: A translational roadmap for reproducible, equitable deployment of multi-omics and AI in colorectal cancer
- 13 January 2026
- journal article
- editorial
- Published by Springer Nature in Medical Oncology
- Vol. 43 (2) , 116
Abstract
Recent advances in Medical Oncology highlight the integration of bulk and single-cell transcriptomics to reveal glycolytic heterogeneity in colorectal cancer. Translating these discoveries into reliable clinical tools requires rigorous methods, transparent validation, and equity-minded implementation. This communication proposes a standards-first roadmap for reproducible and globally relevant biomarker development. It identifies major technical pitfalls such as batch-effect over-correction and normalization bias, and recommends the application of internationally recognized frameworks—TRIPOD + AI, PROBAST + AI, and DECIDE-AI—to ensure transparency, calibration, and staged clinical evaluation. Orthogonal validation using metabolic imaging and spectroscopy is emphasized to confirm biological realism beyond transcriptomic data. The roadmap concludes with strategies for global equity, including LMIC-inclusive trial design, FAIR data standards, and cost-aware clinical surrogates. This structured approach bridges discovery science with practical implementation, aligning precision oncology with reproducibility, accountability, and global accessibility.Keywords
This publication has 14 references indexed in Scilit:
- Machine learning integration of bulk and single-cell RNA-seq data reveals glycolytic heterogeneity in colorectal cancerMedical Oncology, 2025
- SpaNorm: spatially-aware normalization for spatial transcriptomics dataGenome Biology, 2025
- PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methodsBMJ, 2025
- FDG-PET/MRI in colorectal cancer care: an updated systematic reviewAbdominal Radiology, 2024
- Library size confounds biology in spatial transcriptomics dataGenome Biology, 2024
- TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methodsBMJ, 2024
- A standard for sharing spatial transcriptomics dataCell Genomics, 2023
- In-vivo magnetic resonance spectroscopy of lactate as a non-invasive biomarker of dichloroacetate activity in cancer and non-cancer central nervous system disordersFrontiers in Oncology, 2023
- From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatmentCell, 2023
- Prediction value of 18F-FDG PET/CT intratumor metabolic heterogeneity parameters for recurrence after radical surgery of stage II/III colorectal cancerFrontiers in Oncology, 2022